Data from the PERSEUS trial support the FDA approval of the subcutaneous daratumumab-containing regimen in newly diagnosed multiple myeloma.
Approval Alert | Subcutaneous Daratumumab Combo in Newly Diagnosed Multiple Myeloma
Advertisement
Advertisement
Trending on CancerNetwork
1
Resecting MRI-Detected Disease Doesn’t Improve Outcomes in Early-Stage BC
2
Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer
3
Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC
4
Frontline Giredestrant Displays IDFS Improvement vs SOC ET in ER+/HER2– BC
5
